VistaGen Therapeutics
Yahoo Finance • 27 days ago
Biggest stock movers Thursday: MU, LULU and more
[Financial Analyst Working on a Computer with Multi-Monitor Workstation with Real-Time Stocks, Commodities and Foreign Exchange Charts. Businessman Works in Investment Bank City Office at Night.] gorodenkoff Wall Street's main indexes tic... Full story
Yahoo Finance • 28 days ago
US Equity Markets Fall as Technology Stocks Slump Amid Oracle Concerns
US equity indexes fell Wednesday as technology stocks dropped amid financing concerns for an Oracle PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story
Yahoo Finance • last month
Vistagen appoints Nick Tressler as CFO
* Vistagen (NASDAQ:VTGN [https://seekingalpha.com/symbol/VTGN]) announced [https://seekingalpha.com/pr/20323529-vistagen-appoints-nick-tressler-as-chief-financial-officer] on Monday the appointment of Nick Tressler as CFO, effective from... Full story
Yahoo Finance • 2 months ago
Vistagen targets NDA submission for fasedienol in mid-2026 as PALISADE-3 study nears data readout
Earnings Call Insights: Vistagen Therapeutics (VTGN) Q2 2026 MANAGEMENT VIEW * President and CEO Shawn Singh announced "another major milestone in our PALISADE program. The last patient completed the randomized double-blind portion of... Full story
Yahoo Finance • 5 months ago
VistaGen Therapeutics Inc Q1 Sales Increase
(RTTNews) - VistaGen Therapeutics Inc (VTGN) announced Loss for first quarter of -$15.10 million The company's bottom line came in at -$15.10 million, or -$0.47 per share. This compares with -$10,73 million, or -$0.35 per share, last yea... Full story
Yahoo Finance • 7 months ago
Vistagen appoints Elissa Cote as Chief Corporate Development Officer
SOUTH SAN FRANCISCO - Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company with a market capitalization of approximately $61 million, has appointed Elissa Cote as Chief Corporate Development Officer, according to a press... Full story
Yahoo Finance • 7 months ago
Stifel reiterates buy rating on VistaGen stock amid clinical progress
Stifel maintained its buy rating and $12.00 price target on VistaGen Therapeutics (NASDAQ:VTGN) following the company’s fiscal year 2025 update. Currently trading at $2.16, the stock appears undervalued according to InvestingPro analysis.... Full story
Yahoo Finance • 7 months ago
Earnings call transcript: Vistagen's focus on innovation amid rising expenses Q1 2025
Vistagen Therapeutics held its Q1 2025 earnings call, highlighting increased research and development expenses and a strategic focus on its innovative pipeline. Despite a net loss of $51.4 million, the company remains committed to advancin... Full story
Yahoo Finance • 7 months ago
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of this year PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Company show... Full story
Yahoo Finance • 3 years ago
Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., September 09, 2022--(BUSINESS WIRE)--Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individua... Full story
Yahoo Finance • 3 years ago
2 “Strong Buy” Penny Stocks That Could Go Boom
Between the Fed's aggressive policy tightening to rein in inflation and deteriorating economic data, volatility has become a seemingly ever-present facet of the stock market. While the current economic landscape has spurred fear among inve... Full story
Yahoo Finance • 4 years ago
VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update
Completed last patient out milestone for PALISADE-1 Phase 3 clinical trial of PH94B in social anxiety disorder (SAD). Topline results for PALISADE-1 anticipated mid-2022. PALISADE-2 on track for topline readout in late 2022. Received FDA c... Full story
